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Abstract
Background: The global prevalence of diabetes among adults will be 6.4% in 2010 and will increase to 7.7% by 2030. 
Diabetes doubles the odds of depression, and 9% of patients with diabetes are affected by depressive disorders. When 
subclinical depression is included, the proportion of patients who have clinically relevant depressive symptoms 
increases to 26%. In patients aged over 65 years, the interaction of diabetes and depression has predicted increased 
mortality, complications, disability, and earlier occurrence of all of these adverse outcomes. These deleterious effects 
were observed even in minor depression, where the risk of mortality within 7 years was 4.9 times higher compared 
with diabetes patients who did not have depressive symptoms. In this paper we describe the design and methods of 
the Minor Depression and Diabetes trial, a clinical trial within the 'Competence Network for Diabetes mellitus', which is 
funded by the German Federal Ministry of Education and Research.
Methods/Design: Patients' inclusion criteria are: Type 2 diabetes mellitus, 65 to 85 years of age, 3 to 6 depressive 
symptoms (minor depression or mild major depression). Our aim is to compare the efficacy of diabetes-specific 
cognitive behavioural therapy adapted for the elderly vs. intensified treatment as usual vs. a guided self-help 
intervention regarding improvement of health related quality of life as the primary outcome. The trial will be 
conducted as a multicentre, open, observer-blinded, parallel group (3 groups) randomized controlled trial. Patients will 
be randomized to one of the three treatment conditions. After 12 weeks of open-label therapy in all treatment 
conditions, both group interventions will be reduced to one session per month during the one-year long-term phase 
of the trial. At the one-year follow-up, all groups will be re-examined regarding the primary and secondary parameters, 
for example reduction of depressive symptoms, prevention of moderate/severe major depression, improvement of 
glycaemic control, mortality, and cost effectiveness. Depending on additional funding, the sample will be continuously 
observed as a prospective cohort; the primary outcome will be changed to mortality for all subsequent follow-up 
measurements.
Trial registration: Current Controlled Trials Register (ISRCTN58007098).
Background
Diabetes is a worldwide problem with devastating
human, social, and economic impacts. The global preva-
lence of diabetes among adults aged 20-79 years will be
6.4%, affecting 285 million adults, in 2010 and will
increase to 7.7% (439 million adults) by 2030 [1]. The
increase in the proportion of people 65 years of age and
older appears to be an important demographic change
that affects the prevalence of diabetes across the world
[2]. Even when the known high rate of undiagnosed type
2 diabetes [3] is not taken into account, it can be esti-
mated that more than eight million people are currently
affected by diabetes in Germany [4]. With regard to the
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German population, the prevalence of diagnosed diabetes
is nearly 8%; if we consider the estimated number of
unreported cases, the prevalence actually is nearly 10%
[4]. In addition to medical complications, e.g. microvas-
cular complications [5], coronary heart disease [6], poly-
neuropathy [7], and vascular consequences [8], diabetes
is extremely costly in economic terms. As a result of the
high burden of illness and related comorbidities, diabetes
has a considerable impact on quality of life, mortality, and
the social insurance system. The direct medical expendi-
tures as well as indirect costs attributable to diabetes in
the US were estimated at $174 billion for 2007 [9], includ-
ing $116 billion in excess medical care and $58 billion in
reduced national productivity. In Germany, the total cost
of diabetes was calculated at € 22 billion for the year 2001
[10]. Thus, the tremendous medical and economic bur-
dens of diabetes make the disease an important clinical
and public health problem.
There is an additional increase in health-service costs
of 50%-75% when depression occurs together with diabe-
tes [11]. People with diabetes are twice as likely to suffer
from depression compared with the general population,
with a pooled prevalence of 9% for depressive disorders
based on diagnostic interviews and 26% based on self-
report scales in controlled studies [12]. There is a strong
body of evidence for multiple adverse interactions
between diabetes and depression. Thus, depression is
considered to be a risk factor for the development of dia-
betes mellitus. Moreover, the comorbidity of depression
and diabetes is associated with adverse diabetes out-
comes. Among patients aged over 65 years, the interac-
tion of diabetes and depression has predicted increased
mortality, complications, and disability, as well as an ear-
lier occurrence of all these adverse outcomes. These dele-
terious effects were observed even in minor depression,
where the risk of mortality within seven years was 4.9
times higher compared with diabetes patients who did
not have depressive symptoms [13]. The elderly are the
fastest growing segment of the European population.
Depressive symptoms are a major public health problem
in this population subgroup because they are common
and are associated with considerable morbidity and
increased mortality. Prevalence rates of 9.7% were shown
i n  a  G e r m a n  s a m p l e  o f  p r i m a ry - c a r e  p a t i e n t s  a g e d  7 5
years and older [14]. However, most elderly persons who
have clinically significant depressive symptoms do not
meet the diagnostic criteria for major depression or dys-
thymic disorder; hence their depressive conditions are
described as minor, subsyndromal, or subthreshold
depression.
Depression has a strong impact not only on medical
outcomes in diabetes but also on psychological and social
outcomes [15,16]; therefore, the treatment of comorbid
depression is increasingly considered essential for the
clinical care of diabetes patients [17]. The described sum-
mary of the evidence for randomised controlled trials
(RCT) treatments for depression in diabetes was based
on a PubMed search. Eleven trials addressed the treat-
ment of depressed diabetes patients in RCTs and were
classified according to the studied interventions [18].
Counselling [19] and cognitive behavioural therapy
(CBT) [20] demonstrated positive results in two trials;
however, generalisability was restricted due to method-
ological limitations (small sample sizes, six-months fol-
low-up, one trial site, and CBT not specific for diabetes).
The most recent trial, which evaluated supportive psy-
chotherapy, showed moderate improvement in depres-
sion according to post-treatment evaluation but not
follow-up data [21]. Three RCTs [22-24] showed that
antidepressants were superior to placebo in treating full-
blown major depression. In the only RCT involving older,
mildly depressed diabetes patients, paroxetine demon-
strated no statistically significant differences compared
with placebo therapy regarding health related quality of
life (HRQoL), glycaemic control, or symptoms of depres-
sion after six months [25]. The effectiveness of algorithm-
based, flexible interventions using a combination of psy-
chological and pharmacological treatments compared
with standard care was evaluated in four RCTs. The psy-
chological modules of these treatments included prob-
lem-solving training [26,27], counselling [28], and
interpersonal therapy [29]. Antidepressants were given
according to the patients' preferences or following a pre-
defined treatment algorithm. Three trials [25-27] pro-
vided evidence of successful treatment of depression. An
additional RCT, which included elderly depressed diabe-
tes patients (among others), showed that patients in the
mixed treatment condition were less likely to die over the
course of a five year interval than patients treated with
usual care (adjusted hazard ratio 0.49, 95% CI [0.24, 0.98])
[28]. The mixed approaches provide at present the best
available scientific evidence of successful treatment of
depression.
In sum, there are encouraging findings that depression
can be treated successfully in diabetes patients. Regarding
metabolic control, SSRIs may have moderately beneficial
results in trials with sufficient statistical power, while
CBT and counselling for depression seem to have rela-
tively positive short-term results. However, the superior-
ity of one of these two approaches has not been
demonstrated yet; neither has it been possible to genera-
lise these results.
Up to now, no trial was found that directly compared
cognitive behavioural therapy (CBT) with intensified
treatment as usual (TAU) for older patients with diabetes
type 2 and minor depression or mild major depression.
Therefore, the aim of the present trial is to evaluate the
efficacy of diabetes-specific CBT vs. an intensified TAUPetrak et al. BMC Geriatrics 2010, 10:21
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vs. a guided self-help intervention (SH) among elderly
patients (65-85 years of age). CBT treatment has been
tested in several trials and has been approved for treating
depression among the elderly. TAU is an intensified form
of the standard procedure of the German health care and
health insurance systems. Currently, the best treatment
for minor or mild depression among elderly diabetes
patients has not been identified. Antidepressants are not
superior to placebo, and psychosocial interventions have
not been tested in this patient group. Hence, TAU is the
best control group (with reasonable safety aspects) to test
the superiority of a new psychosocial treatment. In order
to control for the effect of a group intervention and to
demonstrate specific efficacy, the guided self-help inter-
vention 'Successful ageing with Diabetes' (SH) is a reason-
able comparator and represents a usual group setting in
Germany.
Methods/Design
Trial objectives and endpoints
The primary hypothesis of the MIND-DIA trial is that
CBT is significantly and clinically more effective than
TAU in terms of improvement of health related quality of
life (HRQoL) at a one-year follow-up. Therefore, HRQoL
(mental component) is analysed as the primary outcome
parameter of the present trial.
The secondary hypotheses comprise the assumptions
that CBT offers a specific advantage and is significantly
more effective than SH, as demonstrated by a signifi-
cantly greater improvement in HRQoL compared with
SH groups at the one-year follow-up. Furthermore, it is
surmised that at the one-year follow-up CBT will be
found to be significantly more effective than TAU in
terms of reduction of depressive symptoms and preven-
tion of moderate/severe major depression, improvement
of glycaemic control (HbA1c), prevention of mortality
(yearly follow-up evaluations with mortality as an addi-
tional endpoint are planned depending on subsequent
funding), and cost effectiveness (direct treatment costs:
medication, hospitalisation and other costs over a period
of one year).
Trial design
The trial will be conducted as a multicentre, open,
observer-blinded, parallel groups (3 groups) randomized
controlled trial (RCT). 'Observer-blinded' means that
treatment evaluations will be conducted by blinded asses-
sors. Further blinding is not possible, given the compari-
son of clearly identifiable group interventions with
treatment as usual. All eligible type 2 diabetes patients
within the age range of 65 to 85 years who give informed
consent will be screened at the participating trial sites in
the multicentre trial. All patients with minor depression
or mild major depression (3 to 6 depression symptoms
according to DSM-IV-TR criteria) will be included in the
trial, provided that they meet the other inclusion and
exclusion criteria. Patients included in the MIND-DIA
trial will be randomized to one of the three treatment
conditions: CBT , SH or TAU. In all groups patients will
receive diabetological treatment as usual by their treating
physicians during the trial. After 12 weeks of open-label
therapy, both group interventions will be reduced to one
session per month in the long-term phase of the trial (12
additional months). At the 12-month follow-up, all
groups will be re-examined regarding the primary out-
come variable and all secondary variables. A first analysis
is planned after the end of the short-term phase of the
RCT without the analyses of the parameters for depres-
sion and HRQoL. Therefore, this interim analysis will not
influence the primary results or the conduct of the trial.
For the first funding phase, the duration of the MIND-
DIA trial is expected to be approximately 36 months.
Recruitment of patients started in May 2009. The trial
design is shown in figure 1.
Trial sample
A total of 315 subjects will be included in the trial.
Patients will be recruited in approximately 20 centres that
specialise in diabetes treatment in the Rhine-Main and
Ruhr areas. In the participating centres, all 65- to 85-
year-old patients with type 2 diabetes who give informed
consent will be screened in a two-stage procedure
(Patient Health Questionnaire (PHQ-9) [30] followed by
the Structured Clinical Interview for DSM IV Disorders
(SCID) [31]. All patients with minor depression or mild
major depression will be included in the trial. Other
inclusion and exclusion criteria of the trial are listed
below.
Inclusion criteria
• type 2 diabetes mellitus diagnosed at least 6 months
before entering the trial
• 65 to 85 years of age
• minor depression (adapted from the DSM-IV-TR
research criteria: we require 3 to 4 symptoms rather
than 2 to 4 symptoms or mild major depression
(according to DSM-IV-TR criteria, 5 to 6 depressive
symptoms); a past history of major depression is not
an exclusion criterion
• living near the coordinating institution where treat-
ment will take place
• written informed consent given
Exclusion criteria
• serious violent, homicidal, or suicidal ideation, par-
ticularly clinically significant suicide risk or history of
attempted suicide within the past 2 years
• history of schizophrenia, psychotic symptoms, or
bipolar disorderPetrak et al. BMC Geriatrics 2010, 10:21
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• organic brain syndrome, dementia, or substantial
cognitive impairment (according to the three-step
MCI screening)
• alcohol or substance abuse or dependence in the
past 12 months (other than nicotine abuse/depen-
dence)
• insufficient ability to understand German
• regular participation in a self-help group (minimum
4 sessions in the past 12 months)
• psychotherapy (in the past 3 months)
• bereavement and grief reaction (loss < 3 months)
• planned hospital admission within the next 3
months
• medical contraindication for physical activity
• history of severe, acute or chronic medical disorder
(other than diabetes), which probably would impede
commitment to the trial or lead to biased trial results
(based on the critical appraisal of the investigator)
• patients who have taken antidepressants or mood-
stabilising medication regularly over the 30 days prior
to screening, patients who have taken fluoxetine regu-
larly over the 60 days prior to screening, or patients
on depot neuroleptic medication over the 5 inter-
injection intervals prior to screening
• blood chemistry ALT and/or AST value(s) greater
than or equal to three times the upper limit of normal
prior to randomization; estimated GFR lower than 30;
blood chemistry TSH values lower than 0.5 mlU/L or
greater than 5 mlU/L adapted to reference ranges of
the laboratory
• legal incompetence or legal guardianship
• participation in competing trials
Trial interventions
Patients included in the MIND-DIA trial will be random-
ized to one of the three treatment arms. Within group
interventions, all sessions will be videotaped and super-
vised by psychotherapists. Adherence to treatment will
be evaluated by a rating system.
(1) CBT is a manualised diabetes-specific cognitive
behavioural therapy, delivered by trained psychologists in
small groups (4 to 8 participants) in an outpatient setting.
CBT is based on a manualised programme (12 weekly
sessions) designed for older adults with type 2 diabetes;
Figure 1 Design of the MIND-DIA trial.
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the treatment includes cognitive and behavioural strate-
gies to overcome depression and diminish diabetes-
related distress, reduce perceived barriers to various
aspects of self-management, increase physical activity,
and enhance coping skills. Central elements are psychoe-
ducation, support, problem solving, pleasant activities,
s c h e d u l i n g  o f  p h y s i c a l  a c t i v i t y  b y  u s e  o f  p e d o m e t e r s ,
thought-control techniques, cognitive restructuring,
Socratic dialogue, training in social skills and interper-
sonal contact, crisis intervention, and emergency plan-
ning. In terms of a workbook, theoretical background,
worksheets, and exercises are given to the patients. An
important element of the CBT condition is the adoption
of pedometers to increase patients' activity levels. For
seven days prior to the start of the intervention, patients
will wear a sealed pedometer to determine their baseline
activity. During the first week of the trial, patients will not
change their usual activity level. At the start of the inter-
vention, there will be one session in which information
will be provided to the patients about the link between
the amount of walking and improvements in health and
about general consequences of doing more walking.
Patients will be asked to set themselves specific weekly
(or monthly) goals regarding the number of steps they
will take based on their individual baseline measure-
ments. In addition to the daily step measurements, the
number of steps will be recorded by the pedometer on a
weekly basis. Furthermore, patients will receive weekly
feedback on their physical activity level in the form of
graphic and written information. After 12 weeks of open-
label therapy, the CBT intervention will be reduced to
one session per month during the long-term phase of the
trial. The topics of the short-term sessions will be repli-
cated during the long-term phase in order to increase the
therapeutic power of the intervention.
(2) The manualised, guided self-help intervention 'Suc-
cessful ageing with Diabetes' (SH), with a focus on living
and ageing with diabetes, will be delivered by trained
moderators (elder-care nurses, nurses, educators, or oth-
ers). Moderators should pay attention, be empathetic,
and give support to all patients. The guided self-help
intervention will provide an intact community and a
sense of belonging. This procedure will enable the inves-
tigators to control for unspecific group effects due to par-
ticipation in a social network of people who share the
same problems; such participation may reduce social or
emotional isolation. The moderators should promote
reciprocal caring and the sharing of relevant information
regarding diabetes and ageing. The primary value of this
group condition will be the mutual aid offered by mem-
bers to one another. Therefore, no formal therapeutic
aspects will be involved; moderators should restrict their
function to guiding the group and giving support. The
intervention is based on a manualised programme, which
comprises only recommendations for group sessions.
Patients primarily choose the topics or group activities.
Thematically, the intervention modules will be compara-
ble to the programmes of German self-help groups; such
programmes consist of spontaneous conversation or sev-
eral group activities.
(3) The participants in the TAU group and their treat-
ing physicians will receive diagnostic feedback regarding
minor or mild depressive symptoms and cognitive func-
tion. Furthermore, feedback on the therapeutic options
will be given to the physicians if minor or mild depressive
symptoms are diagnosed. For minor depression or
depressive symptoms on a subclinical level, the following
treatment options, including combinations of them, are
generally possible:
• 'watchful waiting' (to await the spontaneous remis-
sion of the disorder)
• psychotherapy and/or physical activity
• currently, there is no scientific evidence for medical
treatment with antidepressants in elderly diabetes
patients with minor depression, but a treatment
attempt with a well-tolerated antidepressant (e.g. ser-
traline or citalopram) could be an optional medical
intervention.
However, any treatment option may be chosen, since
care as usual for sub-threshold depression is currently
not formalised.
Outcome measures
The primary outcome variable is HRQoL as measured by
the Short Form-36 [32]: z-values will be obtained by z-
transformation of the SF-36 Mental Component Sum-
mary score based on means and standard deviations of
age- and gender-matched reference groups from the Ger-
man general population. This transformation will be per-
formed because it is known that in some respects HRQoL
decreases differently with age for men and women.
Because the level of depressive symptoms is already rela-
tively low in patients with subthreshold depression com-
pared with patients who have major depression
(notwithstanding a comparably low HRQoL), the possi-
bility for improvement is reduced ('bottom effect').
Hence, when one assesses the efficacy of an intervention
in this specific group, it seems reasonable to analyse, in
additional studies, other important variables, e.g.
HRQoL, as the primary outcome variable and depressive
symptoms as a secondary variable among others. Results
of our own research demonstrated that HRQoL is
extremely reduced among diabetes patients with depres-
sive symptoms: Differences in SF-36 z-values were -1.4
for the physical and -1.9 for the mental component, a
finding that indicates that a bottom effect is not to be
expected in HRQoL.Petrak et al. BMC Geriatrics 2010, 10:21
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Secondary outcome variables are: HRQoL (physical
component as measured by the Physical Component
Summary Score), reduction of depressive symptoms
(Quick Inventory of Depressive Symptomatology-Clini-
cian Rated, QIDS-C-16 [33]; Hamilton Depression Scale,
HAMD [34]), prevention of moderate/severe major
depression (Depression module, SCID), improvement of
glycaemic control (HbA1c), prevention of mortality, and
cost-effectiveness. Standardised rater training of evalua-
tors who were blind to treatment conditions was carried
out for observer-derived depression assessments (QIDS-
C, HAMD, SCID).
Other psychometric questionnaires used in the present
trial are: PAID, Problem Areas in Diabetes [35,36]; FKV-
15, Freiburger Fragebogen zur Krankheitsverarbeitung
(15-Item-Version) [37]; RSE, Rosenberg Self-Esteem
Scale [38]; SDSCA, Summary of diabetes self-care activi-
ties measure [39]; H-Skala, Hopelessness Scale [40]; and
K-INK, Inkongruenzfragebogen [41]. Economic evalua-
tion will be performed alongside the MIND-DIA clinical
trial over the course of the complete trial period. Costs
and effects will be discounted at the rate recommended
by the German guidelines for economic evaluation issued
by the Institute for Quality and Efficiency in the Health
Care Sector (IQWiG); the rate currently is 3%. The three
outcomes estimated for the economic analysis will be
depression-free years, quality adjusted life years (QALYs),
and cumulative cost accrued in each arm of the trial. A
detailed protocol of the cost-effectiveness analysis along-
side the MIND-DIA study was published previously [42].
In addition, mild cognitive impairment (MCI) will be
identified by a three-step MCI diagnostic instrument.
The MCI parameter will be used as a predictor for treat-
ment response in the CBT group. It is expected that
patients with MCI will show poorer responses to the
treatment compared with patients without MCI. In a first
step all patients will be screened by the semi-quantitative
interview according to Strawbridge [43] via telephone or
face to face by research assistants. Those patients who
report memory decline within the past year will be
s c r e e n e d  i n  a  s e c o n d  s t e p  b y  t h e  M i n i - M e n t a l  S t a t e
Examination [44]. Patients who score less than 25 points
but more than 16 points on the MMSE will be screened in
a third step by the following instruments: Clinical
Dementia Rating (CDR) [45], Syndrom Kurztest (SKT)
[46], and Mehrfachwahl-Wortschatz-Intelligenztest
(MWTB) [47]. Early Alzheimer's dementia or substantial
cognitive impairment will be an exclusion criterion for
the trial. All patients who are excluded in the baseline
phase of the trial will receive support to arrange an elabo-
rate medical diagnostic evaluation. Initially, MCI-positive
patients will be included in the trial but screened again at
a 1-year follow-up by the MMSE. Endpoints, measuring
instruments, and time of data collection are shown in
table 1.
Statistical analysis
Sample size calculation
The power calculation is based on expected differences in
SF-36 z-scores. Based on our own comparison of type 2
diabetes patients with mainly untreated depression ver-
sus non-depressed patients, we assume differences of δ =
0.6 between CBT and TAU and of δ = 0.4 between CBT
and SH. For the latter comparison, a significant difference
can be detected with a power of 90% if n = 132 patients
per intervention group are enrolled (2-sided t-test, α =
0.05). Given 132 patients in the CBT group, it is sufficient
to enroll 51 patients in the TAU group to achieve a power
of 95% for the comparison CBT vs. TAU. We therefore
plan to recruit a total number of 315 patients (132 in
CBT, 132 in SH, and 51 in TAU). We expect a rate of loss
to follow-up of 20% in light of our experiences in the
ongoing Depression and Diabetes (DAD) study and
assuming that mortality will play a role in our sample
because of the age of the patients. Analyses will be per-
formed using an intent-to-treat principle (ITT) that
includes all randomised subjects in the groups to which
they were assigned. The last observation carried forward
method (LOCF) will be used for the handling of missing
data due to dropouts. The primary population for analy-
sis is the ITT population. To fully appreciate the potential
influences of missing responses and the LOCF method
chosen as imputation procedure, additional sensitivity
analyses examining the effects of different imputation
methods will be performed and discussed.
Analysis of outcome variables
There will be one analysis of depression and health
related quality of life after completion of the trial, i.e. no
interim analyses are planned for the primary parameters.
The primary response variable is the z-transformed SF-
36 Mental Component Summary (MCS) score at the one-
year follow-up. We plan to employ a linear regression
model of z-transformed SF-36 score on type of interven-
tion and baseline score. Additional variables (e.g. gender,
age, centre, and illness severity) may be included in the
model, if indicated.
The hypotheses will be ordered hierarchically (1: CBT
vs. TAU, 2: CBT vs. SH); the second hypothesis will be
tested at a two-sided 5% level only if the first test is signif-
icant at a two-sided 5% level. Analyses will be performed
using an intent-to-treat analysis, and the last observation
carried forward method will be used for the handling of
missing data. Secondary outcomes (HRQoL (physical
component), severity of depression, prophylaxis of mod-
erate/severe major depression, glycaemic control
(HbA1c), and mortality) will be analysed primarily in a
descriptive manner. For binary response variables, thePetrak et al. BMC Geriatrics 2010, 10:21
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Table 1: Endpoints, measuring instruments, and time of data collection
Endpoint of 
the economic 
evaluation
Derived from/
questionnaire 
name
Time of measurement (Month)
B a s e l i n e M  3M  6M  9M  1 2 M  1 5
Incidence rate 
of depression
Depression 
module of the 
SCID
XX X
Severity of 
depression
QIDS/Hamilton 
Scale
XX XX
QALYs SF-36
EQ-5D
XXXXXX
MCI (three-step 
screening)
Interview of 
Strawbridge
MMSE
CDR
SKT + MWTB
X X*
Health sector 
and patients' 
costs
Cost 
questionnaire
XXX X
Laboratory 
parameters
Safety 
parameters: 
ALT, AST, 
creatinine, TSH
X
HbA1c XXXXXX
Diabetes-
related 
emotional 
distress, coping, 
diabetes self-
care activities
PAID
SDSCA
FKV-15
XX XX
Interpersonal 
aspects
SE
H-Skala
K-INK
XX XX
*those patients with a positive MCI screening at baseline
numbers and proportion of responders will be presented
together with 95% confidence intervals for the propor-
tions; continuous variables will be analysed by use of
summary statistics. If differences between intervention
groups are investigated, outcomes will be adjusted for
baseline values through use of appropriate models (linear,
logistic, or Poisson regression); however, the p-values for
such secondary analyses may not be interpreted as confir-
matory findings. Subgroup analyses stratified for gender
(male/female), mild cognitive impairment (yes/no), and
number of previous depressive episodes (<3, ≥3) also will
be carried out. These analyses will be conducted using
the same methods as those for the full population. Time
to onset of moderate/severe major depression and con-
version rates to dementia will be analysed using Kaplan-
Maier estimates.
Safety
Differences between the treatment groups regarding rates
of mortality and suicidality will be described descrip-
tively. P-values from Fisher's exact test for pairwise com-Petrak et al. BMC Geriatrics 2010, 10:21
http://www.biomedcentral.com/1471-2318/10/21
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parison may be calculated but not interpreted in a
confirmatory manner.
Ethical aspects
The procedures set out in the trial protocol regarding the
conduct, evaluation, and documentation of this trial are
designed to ensure that all persons involved in the trial
abide by Good Clinical Practice (GCP) and the ethical
principles described in the current revision of the Decla-
ration of Helsinki. Clinical monitoring, data manage-
ment, and biometry according to GCP will be conducted
by IZKS Mainz. The trial will be carried out in keeping
with local legal and regulatory requirements. All patients
will be in treatment, regularly seen by diabetologists and
trial clinicians. Before being admitted to the clinical trial,
the patients must agree to participate after the nature,
scope, and possibleconsequences of the trial have been
explained in a form understandable to them. The patients
must give written informed consent. A copy of the signed
consent document must be given to each patient. The
documents must be in language that is understandable to
the patients and must specify who informed them. Dur-
ing the trial, patients will be identified solely by means of
year of birth and an individual identification code
(patient number, randomisation number). For protection
of these data, organisational procedures will be imple-
mented to prevent distribution of the data to unauthor-
ised persons. The appropriate regulations of local data
legislation will be followed in their entirety. Five indepen-
dent ethics committees voted their approval of these pro-
cedures. The main ethics committee for the MIND-DIA
trial is the local Medical Ethics Committee (Ethikkom-
mission bei der Landesärztekammer Hessen); approval
has been given on 09/04/2009. Further ethic committees
which approved the MIND-DIA trail are: the local Medi-
cal Ethics Committee (Ethikkommission der Ärztekamm-
er Nordrhein), the local Medical Ethics Committee
(Ethikkommission der Ärztekammer Westfalen-Lippe)
and the Ethics Committees of the Ruhr-University
Bochum and the Johann-Wolfgang Goethe University,
Frankfurt.
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